Senokot Extra Strength

Produit de santé naturel homologué au Canada

Titulaire: iNova Pharmaceuticals (Australia) Pty Limited
NPN ou DIN-HM: 80079292
Statut: Licence active
Date de licence: 31 juillet 2017
Date de révision: 7 janvier 2025
Forme: Comprimé
Voie d'administration: Orale
Type de demande: Non traditionnelle

Si ce produit était vendu en France

Aucun point relevé par les règles que nous appliquons.

Une quantité quotidienne est calculée uniquement pour une posologie adulte orale explicite, exprimée par jour et dans une unité solide correspondant à la forme du produit. Les unités ambiguës, liquides, poudres et doses pédiatriques ne sont pas extrapolées. Une quantité non calculée n'est pas comparée aux limites de dose. Cette analyse ne constitue pas une autorisation de vente en France ni une évaluation de sécurité ou d'efficacité.

Composition

Ingrédient médicinal et source	Par unité posologique, selon la source	Par jour au plus, adulte
Sennoside A&B Source : Senna alexandrina - Fruit	17,2 milligramme	Non calculée

Ingrédients non médicinaux

Cellulose microcristalline, Stéarate de magnésium, Amidon de maïs

Doses recommandées au Canada

Population	Âge	Quantité par prise	Fréquence
Enfants	minimum : 6 ans ; maximum : 12 ans	1 Comprimé	minimum : 1 jour ; maximum : 2 jours
Adultes	Non précisée	minimum : 1 Comprimé ; maximum : 2 Comprimé	minimum : 1 jour ; maximum : 2 jours

Usages autorisés au Canada

Gentle relief of occasional constipation. Promotes bowel movement.

Un usage autorisé au Canada n'est pas une allégation de santé autorisée dans l'Union européenne. Consultez le registre des allégations de santé.

Mises en garde au Canada

Contre-indications
Do not use if you are hypersensitive to the active substance (sennosides) or to any ingredient in the formulation; have an acute surgical abdomen; abnormal constrictions of the gastrointestinal tract; potential or existing intestinal blockage and stenosis; ileus; atonic bowel; appendicitis; inflammatory bowel disease such as Crohn¿s disease or ulcerative colitis; abdominal pain of unknown origin; undiagnosed rectal bleeding and severe dehydration with depleted water or electrolytes.
Effets indésirables connus
Due to the presence of chrysophanic acid in natural senna, Senokot® laxatives may cause discolouration of breast milk, urine, or feces depending on the acidity (yellow-brown discolouration) or alkalinity (red-violet discolouration) of the substance. There is no pathological significance to this discolouration. Urine discolouration (chromaturia), if present, may interfere with the interpretation of laboratory tests. Reversible pigmentation of the colon, i.e. melanosis coli, may also result from prolonged use of senna containing preparations. The adverse reactions listed below are classified according to their incidence (common or uncommon). Common adverse reactions have an incidence of = 1% and include the following: abdominal pain. Uncommon adverse reactions have an incidence of < 1% and include the following: anaphylactic reaction, anaphylactoid reaction, breast milk discolouration, chromaturia, feces discoloured, nausea, rash erythematous, rash maculo-papular, perianal irritation, rectal hemorrhage, urticaria and vomiting. Adverse reactions of unknown frequency include the following: diarrhea, hypersensitivity and pruritus.
Précautions et mises en garde
Reduce dose or discontinue use if you experience abdominal pain, griping (cramps or spasms) and/or diarrhea. Do not use in the presence of fecal impaction and undiagnosed, acute or persistant gastrointestinal complaints (e.g., abdominal pain, nausea, fever or vomiting) as these symptoms can be signs of a potential or existing intestinal blockage or ileus. Consult a healthcare practitioner if symptoms persist or worsen. Hypersensitivity is known to occur, in which case, discontinue use. If rectal bleeding or failure to have a bowel movement occurs, discontinue therapy and consult a physician, as this may indicate a serious condition. Consult a physician prior to use if you are taking thiazide diuretics, corticosteroids, licorice root or other medications or health products which may aggravate electrolyte imbalance. Consult a physician prior to use if you have a kidney disorder or are taking cardiac medications such as cardiac glycosides or antiarrhythmic medications. Long-term use of stimulant laxatives should be avoided as it may lead to impaired function of the intestine, dependence on laxatives, dehydration and electrolyte imbalance (including hypokalemia). Concomitant therapy with other drugs or herbal substances known to induce hypokalemia (e.g. diuretics, adrenocorticosteroids and liquorice root) may enhance the electrolyte imbalance. Prolonged excessive use or misuse of these products may also result in the development of atonic colon. Symptoms and Treatment of Overdosage: The major symptoms of overdose abuse of any stimulant laxative, including those containing senna, are gripping pain and severe diarrhea, leading to excessive water loss (dehydration) and possible electrolyte imbalance (hypokalemia). Treatment should be supportive with generous amounts of fluid. Electrolytes, especially potassium, should be monitored. This is especially important in the elderly. In case of overdose: Call a Regional Poison Control Centre and/or your physician and/or your local emergency number immediately, or go to your local hospital emergency, even if you do not notice any signs or symptoms. Keep all medicines out of the reach of children.